SCHEMBL3362244

SCHEMBL3362244

CNS(=O)(=O)c1cccc(SC)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.57
GAA P10253 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
LMNA P02545 3/20 0.48
TSHR P16473 2/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
HTT P42858 1/20 0.48
TNNI3K Q59H18 5/20 0.46
EGFR P00533 2/20 0.46
SLC6A4 P31645 1/20 0.44
ALDH1A1 P00352 2/20 0.44
ESR1 P03372 1/20 0.42
PTBP1 P26599 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA3 P07451 1/20 0.41
CA4 P22748 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21524696 0.84 HPGD (0.55) HPGDGAAL3MBTL1SMN1; SMN2LMNA
SCHEMBL2242660 0.82 L3MBTL1 (0.61) HPGDGAAL3MBTL1SMN1; SMN2LMNA
SCHEMBL10078922 0.79 HPGD (0.53) HPGDGAAL3MBTL1SMN1; SMN2LMNA
SCHEMBL20048746 0.77 HPGD (0.51) HPGDGAAL3MBTL1SMN1; SMN2LMNA
SCHEMBL26610860 0.77 TSHR (0.52) HPGDGAAL3MBTL1SMN1; SMN2LMNA
SCHEMBL30306605 0.77 HPGD (0.51) HPGDGAAL3MBTL1SMN1; SMN2LMNA
SCHEMBL7136145 0.77 CA2 (0.61) HPGDGAAL3MBTL1SLC6A4CA12
SCHEMBL1805007 0.76 SMN1; SMN2 (0.59) HPGDGAASMN1; SMN2LMNATSHR
SCHEMBL20664204 0.76 GAA (0.45) HPGDGAAL3MBTL1SMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL28261327 0.76 TSHR (0.50) HPGDGAAL3MBTL1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES HTR1A, HTR3B, HTR3A HPGD 3754/4885GAA 1045/4885L3MBTL1 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.